Latest Conference Coverage

Early Data Support Continued Development of NVG-2089 as IVIg Alternative in CIDP

Nuvig's NVG-2089 shows promise in CIDP treatment, offering a safer, more efficient alternative to IVIg with a patient-friendly trial design.

Phase 4 Trial to Test Transition From IVIg to Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy

Investigators explore a phase 4 trial transitioning CIDP patients from IVIg to efgartigimod, aiming to enhance treatment safety and efficacy.

Rituximab’s Effect on NfL Levels Points to Possible Therapeutic Advantage in CIDP

A recent study suggests rituximab may benefit CIDP patients, showing improvement in neurofilament levels and clinical outcomes after treatment.

Enhancing Alzheimer Care in Asian and Pacific Islander Communities Through RCASIA: Brad Kamitaki, MD

Preclinical Study Suggests Stem Cell Therapy EN001 and Insulin May Improve Symptoms of Charcot-Marie-Tooth Disease Type 1A

Researchers reported that both EN001 and insulin improved muscle strength and nerve function in models of Charcot-Marie-Tooth disease type 1A, with combined treatment showing enhanced effects.

Eplontersen Exceeds Established Thresholds for Symptom and Disability Improvement in ATTRv-PN

Newly presented findings from the NEURO-TTRansform study identified thresholds for meaningful improvement in symptoms and disability, which were exceeded by eplontersen treatment.

ATTRv-PN Treatment Vutrisiran Demonstrates Long-Term Efficacy in Open-Label HELIOS-A Extension

New findings confirm vutrisiran's long-term safety and efficacy in treating hereditary transthyretin amyloidosis, enhancing patient quality of life.

Mechanism and Rationale Behind Imlifidase for Guillain-Barré Syndrome: Elisabeth Sonesson, PhD

The vice president and franchise lead of Autoimmune at Hansa Biopharma discussed the rapid, antibody-cleaving mechanism of imlifidase and its potential to address unmet needs in Guillain-Barré syndrome. [WATCH TIME: 3 minutes]

Gene Therapy Atidarsagene Autotemcel Improves Peripheral Neuropathy of Pre-Symptomatic Late-Infantile Metachromatic Leukodystrophy

Gene therapy arsa-cel significantly improves nerve function in children with late-infantile metachromatic leukodystrophy, outperforming traditional treatments.

Real-World Study Highlights Reduced Disability Progression of CIDP With Immunoglobulin Therapy

A recent matched cohort analysis revealed that patients with CIDP treated with immunoglobulin had lower rates of assistive device deterioration and opioid use compared with those untreated.

ANX005 Outperforms IVIg and Plasma Exchange in Improving Guillain-Barré Syndrome Outcomes

Matched analysis from the IGOS dataset showed ANX005-treated patients had greater improvements in GBS disability scores over time compared with those receiving IVIg or plasma exchange.

Outlining Phase 3 VITALIZE and MOBILIZE Trials of Riliprubart in CIDP: Luis Querol, MD, PhD

The neurologist at the Hospital de la Santa Creu, in Barcelona, Spain, outlined the goals and significance of the VITALIZE and MOBILIZE phase 3 trials evaluating riliprubart in standard-of-care and treatment-refractory CIDP populations. [WATCH TIME: 3 minutes]

NeuroVoices: Brad Kamitaki, MD, on Aiming to Improve Dementia Care in Asian and Pacific American Communities

The assistant professor of neurology at Robert Wood Johnson Medical School discussed the mission of RCASIA, highlights from its annual retreat, and key takeaways from AAN 2025.

Riliprubart Demonstrates Maintained Efficacy, Safety in Subgroup Analyses of CIDP

Subgroup data from a phase 2 CIDP trial showed riliprubart maintained consistent efficacy and safety across patient demographics, disease characteristics, and prior treatment exposures.

Sarcopenia Shows Association to Higher Risk of Chemotherapy-Induced Peripheral Neurotoxicity

A newly presented study showed that patients with sarcopenia before starting chemotherapy had a greater likelihood of developing moderate to severe peripheral neurotoxicity.

Biomarker and Subgroup Insights on Novel CIDP Therapy Riliprubart: Luis Querol, MD, PhD

The neurologist at the Hospital de la Santa Creu, in Barcelona, Spain, provided clinical context on sustained responses and new biomarker findings from exploratory phase 2 data on riliprubart in CIDP. [WATCH TIME: 4 minutes]

Eplontersen Slows Disability Progression and Deterioration of Gait Speed in ATTRv Polyneuropathy

Eplontersen showed promise in halting disability progression and improving gait speed in patients with hereditary amyloid polyneuropathy, according to recent study findings.

UK Analysis Shows Low Transthyretin Levels Linked to Increased Risk of Multiple Diseases

A recently presented biobank data analysis showed associations between reduced transthyretin and higher incidence of conditions such as Alzheimer disease, cardiovascular disease, and rheumatoid arthritis.

Investigational Imlifidase Shows Rapid and Sustained Improvement of Guillain-Barré Syndrome Symptoms

Among patients with severe Guillain-Barré syndrome, imlifidase plus IVIg resulted in improved mobility, strength, and disability scores, with sustained benefit over a 6-month time period.

Efficacy of CIDP Treatments Immunoglobulin 10% and Efgartigimod Compared Through Matching-Adjusted Indirect Analysis

A recently presented matching-adjusted indirect comparison assessed outcomes of immune globulin subcutaneous (Human)-ifas, 10% solution versus subcutaneous efgartigimod in patients with CIDP.

A More Selective Immune Approach to CIDP With Riliprubart: Claudia Sommer, MD

The president-elect of the Peripheral Nerve Society provided clinical context the mechanism and clinical relevance of riliprubart, a targeted complement inhibitor in development for chronic inflammatory demyelinating polyneuropathy. [WATCH TIME: 3 minutes]

Carbazole-Based Therapy Carba1 Demonstrates Improvement of Chemotherapy-Induced Neuropathy

Carba1 showed promise in preclinical models as a dual-action agent, protecting against chemotherapy-induced neuropathy while preserving anticancer efficacy and safety.

Phase 2 ARDA Findings Support Development of Empasiprubart in Multifocal Motor Neuropathy

Presented at the 2025 PNS Annual Meeting, phase 2 ARDA data showed empasiprubart reduced IVIg retreatment risk and improved grip strength in patients with MMN.

CIDP Agent Riliprubart Reduces Neurofilament Light in Phase 2 Subanalysis

New data from a phase 2 study presented at the 2025 PNS Annual Meeting showed that riliprubart reduced plasma NfL levels in CIDP, with greater reductions linked to stronger functional improvements.

Tanruprubart Shows Early, Sustained Quality-of-Life Improvements in Phase 3 GBS Trial

Patients with Guillain-Barré syndrome treated with tanruprubart, formerly known as ANX005, reported significant benefits in mobility, self-care, and usual activity compared with placebo.

CRISPR Gene Therapy Nexiguran Ziclumeran Shows Promise in Early-Stage Study of ATTR Amyloidosis With Polyneuropathy

A groundbreaking CRISPR therapy shows promise in treating hereditary ATTR amyloidosis, achieving significant serum TTR reductions and stable patient outcomes.

Key Sessions and Real-World Case Learning at PNS 2025: Kathrin Doppler, MD; Vincent Timmerman, PhD, MSc

A pair of committee chairs for the Peripheral Nerve Society’s Annual Meeting shared key sessions and trends clinicians should follow at the upcoming meeting, emphasizing collaboration, trial data, and clinical relevance. [WATCH TIME: 3 minutes]

Translational Science Reshaping the 2025 PNS Annual Meeting Agenda: Kathrin Doppler, MD; Vincent Timmerman, PhD, MSc

A pair of committee chairs for the Peripheral Nerve Society’s Annual Meeting discussed how this year’s meeting reflects a growing emphasis on therapeutic research and translational progress in peripheral neuropathies. [WATCH TIME: 2 minutes]

Recognizing Scientific Excellence and Impact in Multiple Sclerosis Research: Bruce Bebo, PhD

The executive vice president of research at the National MS Society talked about the significance of the Dystel Prize, honoring researchers in MS whose scientific work has led to meaningful diagnostic or therapeutic advancements. [WATCH TIME: 2 minutes]

Advancing MS Care Through Early Intervention and Deeper CNS Insights: Jack P. Antel, MD

The professor of neurology and neurosurgery at McGill University discussed the evolution of multiple sclerosis treatment, the need for earlier intervention, and the pressing scientific questions surrounding neuroinflammation. [WATCH TIME: 4 minutes]